Patient Characteristics (n = 42)
| Characteristic | Value |
| Age (y) | 73 (70.0–75.2) |
| Baseline PSA (ng/mL) | 329.4 (12.2–646.7) |
| Treatment type (n) | |
| Chemotherapy | 16 |
| Antiandrogen | 19 |
| 223Ra-dichloride | 5 |
| Sipuleucel-T | 2 |
| PET tumor burden measurements | |
| Baseline net TLA (g) | 2,380.8 (706.9–4,054.6) |
| Follow-up net TLA (g) | 1,438.9 (555.0–2,322.8) |
| Baseline net MATV (cm3) | 516.0 (151.9–880.1) |
| Follow-up net MATV (cm3) | 356.1 (135.7–576.4) |
| Sites of disease on first PET/second PET (n) | |
| Bone | 32 (76%)/30 (71%) |
| Lymphatics | 19 (45%)/15 (36%) |
| Prostate | 13 (31%)/12 (29%) |
| Lung and adrenal glands | 3 (7%)/3 (7%) |
Continuous values are expressed as mean followed by 95% confidence interval in parentheses.